Page last updated: 2024-10-21

4-iodo-2,5-dimethoxyphenylisopropylamine and Epilepsy

4-iodo-2,5-dimethoxyphenylisopropylamine has been researched along with Epilepsy in 2 studies

4-iodo-2,5-dimethoxyphenylisopropylamine: RN given refers to unlabeled parent cpd without isomeric designation; a serotonin agonist
2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine : An organoiodine compound that is amphetamine bearing two methoxy substituents at positions 2 and 5 as well as an iodo substituent at position 4.

Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)

Research Excerpts

ExcerptRelevanceReference
" In order to clarify the role of 5-HT2 receptors in epilepsy, the present study examined the effects of a 5-HT2 receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane(DOI) and a 5-HT2 receptor antagonist ketanserin on HIP-kindled seizures."7.68[Serotonergic mechanisms of hippocampal kindled seizures in cats--effects of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and ketanserin]. ( Hasegawa, H; Nakamura, M; Wada, Y; Yamaguchi, N, 1993)
" In order to clarify the role of 5-HT2 receptors in epilepsy, the present study examined the effects of a 5-HT2 receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane(DOI) and a 5-HT2 receptor antagonist ketanserin on HIP-kindled seizures."3.68[Serotonergic mechanisms of hippocampal kindled seizures in cats--effects of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and ketanserin]. ( Hasegawa, H; Nakamura, M; Wada, Y; Yamaguchi, N, 1993)
", ip) indicate that the liver is the primary site of biotransformation of the compound, suggesting that both 22a and its metabolite(s) are active, compensating probably low bioavailability of the parent molecule."1.43Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents. ( Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E, 2016)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Waszkielewicz, AM1
Gunia-Krzyżak, A1
Powroźnik, B1
Słoczyńska, K1
Pękala, E1
Walczak, M1
Bednarski, M1
Żesławska, E1
Nitek, W1
Marona, H1
Nakamura, M1
Wada, Y1
Hasegawa, H1
Yamaguchi, N1

Other Studies

2 other studies available for 4-iodo-2,5-dimethoxyphenylisopropylamine and Epilepsy

ArticleYear
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
    Bioorganic & medicinal chemistry, 2016, Apr-15, Volume: 24, Issue:8

    Topics: Amino Alcohols; Animals; Anticonvulsants; Chemistry, Physical; Dose-Response Relationship, Drug; Dru

2016
[Serotonergic mechanisms of hippocampal kindled seizures in cats--effects of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and ketanserin].
    No to shinkei = Brain and nerve, 1993, Volume: 45, Issue:10

    Topics: Amphetamines; Animals; Cats; Epilepsy; Hippocampus; Ketanserin; Kindling, Neurologic; Receptors, Ser

1993